Arto Urtti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/509230/publications.pdf

Version: 2024-02-01

216 papers

11,689 citations

25014 57 h-index 96 g-index

231 all docs

231 docs citations

231 times ranked

11484 citing authors

#	Article	IF	CITATIONS
1	Inhibition of prolyl oligopeptidase: A promising pathway to prevent the progression of age-related macular degeneration. Biomedicine and Pharmacotherapy, 2022, 146, 112501.	2.5	3
2	Ocular metabolism and distribution of drugs in the rabbit eye: Quantitative assessment after intracameral and intravitreal administrations. International Journal of Pharmaceutics, 2022, 613, 121361.	2.6	14
3	Understanding dexamethasone kinetics in the rabbit tear fluid: Drug release and clearance from solution, suspension and hydrogel formulations. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 172, 53-60.	2.0	13
4	Topical pharmacokinetics of dexamethasone suspensions in the rabbit eye: Bioavailability comparison. International Journal of Pharmaceutics, 2022, 615, 121515.	2.6	7
5	The Effect of Microbubble-Assisted Ultrasound on Molecular Permeability across Cell Barriers. Pharmaceutics, 2022, 14, 494.	2.0	6
6	5-(Sulfamoyl)thien-2-yl 1,3-oxazole inhibitors of carbonic anhydrase II with hydrophilic periphery. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 1005-1011.	2.5	2
7	Pharmacoproteomics of Brain Barrier Transporters and Substrate Design for the Brain Targeted Drug Delivery. Pharmaceutical Research, 2022, 39, 1363-1392.	1.7	19
8	Liposomal sunitinib for ocular drug delivery: A potential treatment for choroidal neovascularization. International Journal of Pharmaceutics, 2022, 620, 121725.	2.6	19
9	Pharmacokinetics of Pullulan–Dexamethasone Conjugates in Retinal Drug Delivery. Pharmaceutics, 2022, 14, 12.	2.0	11
10	Imaging, quantitation and kinetic modelling of intravitreal nanomaterials. International Journal of Pharmaceutics, 2022, 621, 121800.	2.6	12
11	Mechanisms of cellular retention of melanin bound drugs: Experiments and computational modeling. Journal of Controlled Release, 2022, 348, 760-770.	4.8	7
12	Swarms of chemically modified antiviral siRNA targeting herpes simplex virus infection in human corneal epithelial cells. PLoS Pathogens, 2022, 18, e1010688.	2.1	7
13	Quantitative pharmacokinetic analyses of anterior and posterior elimination routes of intravitreal anti-VEGF macromolecules using published human and rabbit data. Experimental Eye Research, 2022, 222, 109162.	1.2	4
14	Exploring the Impact of Morphology on the Properties of Biodegradable Nanoparticles and Their Diffusion in Complex Biological Medium. Biomacromolecules, 2021, 22, 126-133.	2.6	80
15	Diffusion and Protein Corona Formation of Lipid-Based Nanoparticles in the Vitreous Humor: Profiling and Pharmacokinetic Considerations. Molecular Pharmaceutics, 2021, 18, 699-713.	2.3	32
16	Comprehensive Ocular and Systemic Pharmacokinetics of Brinzolamide in Rabbits After Intracameral, Topical, and Intravenous Administration. Journal of Pharmaceutical Sciences, 2021, 110, 529-535.	1.6	12
17	Carboxylesterase Activities and Protein Expression in Rabbit and Pig Ocular Tissues. Molecular Pharmaceutics, 2021, 18, 1305-1316.	2.3	11
18	Intravitreal Polymeric Nanocarriers with Long Ocular Retention and Targeted Delivery to the Retina and Optic Nerve Head Region. Pharmaceutics, 2021, 13, 445.	2.0	26

#	Article	IF	Citations
19	Biopharmaceutics of Topical Ophthalmic Suspensions: Importance of Viscosity and Particle Size in Ocular Absorption of Indomethacin. Pharmaceutics, 2021, 13, 452.	2.0	30
20	Pharmacokinetics of intravitreal macromolecules: Scaling between rats and rabbits. European Journal of Pharmaceutical Sciences, 2021, 159, 105720.	1.9	11
21	Partitioning and Spatial Distribution of Drugs in Ocular Surface Tissues. Pharmaceutics, 2021, 13, 658.	2.0	8
22	Pullulan Based Bioconjugates for Ocular Dexamethasone Delivery. Pharmaceutics, 2021, 13, 791.	2.0	11
23	Cowpea Chlorotic Mottle Virusâ€Like Particles as Potential Platform for Antisense Oligonucleotide Delivery in Posterior Segment Ocular Diseases. Macromolecular Bioscience, 2021, 21, 2100095.	2.1	5
24	Screening of chemical linkers for development of pullulan bioconjugates for intravitreal ocular applications. European Journal of Pharmaceutical Sciences, 2021, 161, 105785.	1.9	9
25	New In Vitro-In Silico Approach for the Prediction of In Vivo Performance of Drug Combinations. Molecules, 2021, 26, 4257.	1.7	9
26	Oxidative Stress and Mitochondrial Damage in Dry Age-Related Macular Degeneration Like NFE2L2/PGC-1αÂ-/- Mouse Model Evoke Complement Component C5a Independent of C3. Biology, 2021, 10, 622.	1.3	4
27	Conformationally Constrained Peptides with High Affinity to the Vascular Endothelial Growth Factor. Journal of Medicinal Chemistry, 2021, 64, 10900-10907.	2.9	5
28	Peptide Inhibitors of Vascular Endothelial Growth Factor A: Current Situation and Perspectives. Pharmaceutics, 2021, 13, 1337.	2.0	14
29	Mucoadhesive properties of nanogels based on stimuli-sensitive glycosaminoglycan-graft-pNIPAAm copolymers. International Journal of Biological Macromolecules, 2021, 186, 864-872.	3.6	17
30	Ocular pharmacokinetics of atenolol, timolol and betaxolol cocktail: Tissue exposures in the rabbit eye. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 166, 155-162.	2.0	16
31	Statins for the prevention of proliferative vitreoretinopathy: cellular responses in cultured cells and clinical statin concentrations in the vitreous. Scientific Reports, 2021, 11, 980.	1.6	8
32	Magnetically Assisted Drug Delivery of Topical Eye Drops Maintains Retinal Function In Vivo in Mice. Pharmaceutics, 2021, 13, 1650.	2.0	5
33	Ultrasound and Microbubbles for the Treatment of Ocular Diseases: From Preclinical Research towards Clinical Application. Pharmaceutics, 2021, 13, 1782.	2.0	10
34	Retinal neuroprotection by controlled release of a VCP inhibitor from self-assembled nanoparticles. Journal of Controlled Release, 2021, 339, 307-320.	4.8	11
35	Electrical synapses interconnecting axons revealed in the optic nerve head – a novel model of gap junctions' involvement in optic nerve function. Acta Ophthalmologica, 2020, 98, 408-417.	0.6	15
36	<i>In situ</i> analysis of liposome hard and soft protein corona structure and composition in a single label-free workflow. Nanoscale, 2020, 12, 1728-1741.	2.8	46

#	Article	IF	CITATIONS
37	Amphiphilic Polypeptides for VEGF siRNA Delivery into Retinal Epithelial Cells. Pharmaceutics, 2020, 12, 39.	2.0	23
38	Polysaccharides in Ocular Drug Delivery. Pharmaceutics, 2020, 12, 22.	2.0	92
39	Ocular Intracameral Pharmacokinetics for a Cocktail of Timolol, Betaxolol, and Atenolol in Rabbits. Molecular Pharmaceutics, 2020, 17, 588-594.	2.3	7
40	Release of functional dexamethasone by intracellular enzymes: A modular peptide-based strategy for ocular drug delivery. Journal of Controlled Release, 2020, 327, 584-594.	4.8	22
41	Topical ocular pharmacokinetics and bioavailability for a cocktail of atenolol, timolol and betaxolol in rabbits. European Journal of Pharmaceutical Sciences, 2020, 155, 105553.	1.9	19
42	Intravitreal hydrogels for sustained release of therapeutic proteins. Journal of Controlled Release, 2020, 326, 419-441.	4.8	76
43	Avoiding the Pitfalls of siRNA Delivery to the Retinal Pigment Epithelium with Physiologically Relevant Cell Models. Pharmaceutics, 2020, 12, 667.	2.0	6
44	Influence of Cell Membrane Wrapping on the Cellâ-'Porous Silicon Nanoparticle Interactions. Advanced Healthcare Materials, 2020, 9, e2000529.	3.9	11
45	Extended Pharmacokinetic Model of the Intravitreal Injections of Macromolecules in Rabbits. Part 2: Parameter Estimation Based on Concentration Dynamics in the Vitreous, Retina, and Aqueous Humor. Pharmaceutical Research, 2020, 37, 226.	1.7	10
46	Ocular barriers to retinal delivery of intravitreal liposomes: Impact of vitreoretinal interface. Journal of Controlled Release, 2020, 328, 952-961.	4.8	49
47	Light-Activated Liposomes Coated with Hyaluronic Acid as a Potential Drug Delivery System. Pharmaceutics, 2020, 12, 763.	2.0	29
48	Microflow-Based Device for In Vitro and Ex Vivo Drug Permeability Studies. SLAS Technology, 2020, 25, 455-462.	1.0	1
49	The effect of prolyl oligopeptidase inhibitors on alpha-synuclein aggregation and autophagy cannot be predicted by their inhibitory efficacy. Biomedicine and Pharmacotherapy, 2020, 128, 110253.	2.5	17
50	Microscale Thermophoresis as a Screening Tool to Predict Melanin Binding of Drugs. Pharmaceutics, 2020, 12, 554.	2.0	17
51	Mitophagy in the Retinal Pigment Epithelium of Dry Age-Related Macular Degeneration Investigated in the NFE2L2/PGC-1α-/- Mouse Model. International Journal of Molecular Sciences, 2020, 21, 1976.	1.8	31
52	Hexosome engineering for targeting of regional lymph nodes. Materialia, 2020, 11, 100705.	1.3	17
53	Characterization, Stability, and In Vivo Efficacy Studies of Recombinant Human CNTF and Its Permeation into the Neural Retina in Ex Vivo Organotypic Retinal Explant Culture Models. Pharmaceutics, 2020, 12, 611.	2.0	8
54	Design and synthesis of lipid-mimetic cationic iridium complexes and their liposomal formulation for in vitro and in vivo application in luminescent bioimaging. RSC Advances, 2020, 10, 14431-14440.	1.7	6

#	Article	IF	Citations
55	Prodrug Approach for Posterior Eye Drug Delivery: Synthesis of Novel Ganciclovir Prodrugs and in Vitro Screening with Cassette Dosing. Molecular Pharmaceutics, 2020, 17, 1945-1953.	2.3	5
56	Role of retinal pigment epithelium permeability in drug transfer between posterior eye segment and systemic blood circulation. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 143, 18-23.	2.0	27
57	Retinal Pigment Epithelial Cell Line with Fast Differentiation and Improved Barrier Properties. Pharmaceutics, 2019, 11, 412.	2.0	11
58	Intravitreal Pharmacokinetics in Mice: SPECT/CT Imaging and Scaling to Rabbits and Humans. Molecular Pharmaceutics, 2019, 16, 4399-4404.	2.3	17
59	Electron dispersive X-ray spectroscopy and degradation properties of hyaluronic acid decorated microparticles. Colloids and Surfaces B: Biointerfaces, 2019, 181, 896-901.	2.5	8
60	Distribution of Small Molecular Weight Drugs into the Porcine Lens: Studies on Imaging Mass Spectrometry, Partition Coefficients, and Implications in Ocular Pharmacokinetics. Molecular Pharmaceutics, 2019, 16, 3968-3976.	2.3	20
61	Establishment of an In Vitro–In Vivo Correlation for Melanin Binding and the Extension of the Ocular Half-Life of Small-Molecule Drugs. Molecular Pharmaceutics, 2019, 16, 4890-4901.	2.3	23
62	Highly hydrophilic 1,3-oxazol-5-yl benzenesulfonamide inhibitors of carbonic anhydrase II for reduction of glaucoma-related intraocular pressure. Bioorganic and Medicinal Chemistry, 2019, 27, 115086.	1.4	10
63	Characterization of artificially re-pigmented ARPE-19 retinal pigment epithelial cell model. Scientific Reports, 2019, 9, 13761.	1.6	26
64	Enhanced Delivery of 4-Thioureidoiminomethylpyridinium Perchlorate in Tuberculosis Models with IgG Functionalized Poly(Lactic Acid)-Based Particles. Pharmaceutics, 2019, 11, 2.	2.0	20
65	CD44 aptamer mediated cargo delivery to lysosomes of retinal pigment epithelial cells to prevent age-related macular degeneration. Biochemistry and Biophysics Reports, 2019, 18, 100642.	0.7	11
66	Exploring Light-Sensitive Nanocarriers for Simultaneous Triggered Antibiotic Release and Disruption of Biofilms Upon Generation of Laser-Induced Vapor Nanobubbles. Pharmaceutics, 2019, 11, 201.	2.0	26
67	Exploring the mucoadhesive behavior of sucrose acetate isobutyrate: a novel excipient for oral delivery of biopharmaceuticals. Drug Delivery, 2019, 26, 532-541.	2.5	9
68	Influence of Melanin Characteristics on Drug Binding Properties. Molecular Pharmaceutics, 2019, 16, 2549-2556.	2.3	21
69	Comment on "Topical Delivery of Avastin to the Posterior Segment of the Eye In Vivo Using Annexin A5â€Associated Liposomes― Topical Liposomal Bevacizumab Results in Negligible Retinal Concentrations. Small, 2019, 15, 1805199.	5.2	8
70	Characterization of CDNF-Secreting ARPE-19 Cell Clones for Encapsulated Cell Therapy. Cell Transplantation, 2019, 28, 413-424.	1.2	11
71	Light-Triggered Cellular Delivery of Oligonucleotides. Pharmaceutics, 2019, 11, 90.	2.0	18
72	Design principles of ocular drug delivery systems: importance of drug payload, release rate, and material properties. Drug Discovery Today, 2019, 24, 1446-1457.	3.2	124

#	Article	IF	CITATIONS
73	Retinal bioavailability of liposomal minocycline after sub-conjunctival administration is low. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 18, 427.	1.7	0
74	Artificially cloaked viral nanovaccine for cancer immunotherapy. Nature Communications, 2019, 10, 5747.	5.8	86
75	Quantitative Protein Expression in the Human Retinal Pigment Epithelium: Comparison Between Apical and Basolateral Plasma Membranes With Emphasis on Transporters., 2019, 60, 5022.		18
76	Modified cells as potential ocular drug delivery systems. Drug Discovery Today, 2019, 24, 1621-1626.	3.2	1
77	Pharmacokinetic Simulations of Intravitreal Biologicals: Aspects of Drug Delivery to the Posterior and Anterior Segments. Pharmaceutics, 2019, 11, 9.	2.0	27
78	Loss of NRF-2 and PGC- $1\hat{1}$ ± genes leads to retinal pigment epithelium damage resembling dry age-related macular degeneration. Redox Biology, 2019, 20, 1-12.	3.9	117
79	Corneal and conjunctival drug permeability: Systematic comparison and pharmacokinetic impact in the eye. European Journal of Pharmaceutical Sciences, 2018, 119, 83-89.	1.9	85
80	Binding of Small Molecule Drugs to Porcine Vitreous Humor. Molecular Pharmaceutics, 2018, 15, 2174-2179.	2.3	16
81	Implications of melanin binding in ocular drug delivery. Advanced Drug Delivery Reviews, 2018, 126, 23-43.	6.6	80
82	Hyaluronic Acid Graft Copolymers with Cleavable Arms as Potential Intravitreal Drug Delivery Vehicles. Macromolecular Bioscience, 2018, 18, 1700200.	2.1	3
83	Expression, activity and pharmacokinetic impact of ocular transporters. Advanced Drug Delivery Reviews, 2018, 126, 3-22.	6.6	42
84	Increased intraocular pressure alters the cellular distribution of HuR protein in retinal ganglion cells $\hat{a} \in \text{Mos}$ A possible sign of endogenous neuroprotection failure. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 296-306.	1.8	10
85	Understanding Molecular Drivers of Melanin Binding To Support Rational Design of Small Molecule Ophthalmic Drugs. Journal of Medicinal Chemistry, 2018, 61, 10106-10115.	2.9	25
86	Cisplatin Encapsulation Generates Morphologically Different Multicompartments in the Internal Nanostructures of Nonlamellar Liquid-Crystalline Self-Assemblies. Langmuir, 2018, 34, 6570-6581.	1.6	33
87	The effect of light sensitizer localization on the stability of indocyanine green liposomes. Journal of Controlled Release, 2018, 284, 213-223.	4.8	43
88	Esterase activity in porcine and albino rabbit ocular tissues. European Journal of Pharmaceutical Sciences, 2018, 123, 106-110.	1.9	27
89	Accelerated pharmaceutical protein development with integrated cell free expression, purification, and bioconjugation. Scientific Reports, 2018, 8, 11967.	1.6	6
90	Extended Pharmacokinetic Model of the Rabbit Eye for Intravitreal and Intracameral Injections of Macromolecules: Quantitative Analysis of Anterior and Posterior Elimination Pathways. Pharmaceutical Research, 2018, 35, 153.	1.7	26

#	Article	IF	CITATIONS
91	Melanin targeting for intracellular drug delivery: Quantification of bound and free drug in retinal pigment epithelial cells. Journal of Controlled Release, 2018, 283, 261-268.	4.8	27
92	LC–MS/MS Based Quantitation of ABC and SLC Transporter Proteins in Plasma Membranes of Cultured Primary Human Retinal Pigment Epithelium Cells and Immortalized ARPE19 Cell Line. Molecular Pharmaceutics, 2017, 14, 605-613.	2.3	45
93	Differentially cleaving peptides as a strategy for controlled drug release in human retinal pigment epithelial cells. Journal of Controlled Release, 2017, 251, 37-48.	4.8	16
94	Impact of Chemical Structure on Conjunctival Drug Permeability: Adopting Porcine Conjunctiva and Cassette Dosing for Construction of In Silico Model. Journal of Pharmaceutical Sciences, 2017, 106, 2463-2471.	1.6	37
95	Pharmacokinetic aspects of retinal drug delivery. Progress in Retinal and Eye Research, 2017, 57, 134-185.	7.3	454
96	Inner Blood–Retinal Barrier Dominantly Expresses Breast Cancer Resistance Protein: Comparative Quantitative Targeted Absolute Proteomics Study of CNS Barriers in Pig. Molecular Pharmaceutics, 2017, 14, 3729-3738.	2.3	26
97	Melanin binding study of clinical drugs with cassette dosing and rapid equilibrium dialysis inserts. European Journal of Pharmaceutical Sciences, 2017, 109, 162-168.	1.9	30
98	Time-Resolved Fluorescence Spectroscopy Reveals Fine Structure and Dynamics of Poly(scp>ls/scp>-lysine) and Polyethylenimine Based DNA Polyplexes. Journal of Physical Chemistry B, 2017, 121, 10782-10792.	1.2	4
99	Multi-parametric surface plasmon resonance platform for studying liposome-serum interactions and protein corona formation. Drug Delivery and Translational Research, 2017, 7, 228-240.	3.0	37
100	Nanofibrillar cellulose-alginate hydrogel coated surgical sutures as cell-carrier systems. PLoS ONE, 2017, 12, e0183487.	1.1	26
101	Isolation of Intact and Functional Melanosomes from the Retinal Pigment Epithelium. PLoS ONE, 2016, 11, e0160352.	1.1	17
102	Olaparib significantly delays photoreceptor loss in a model for hereditary retinal degeneration. Scientific Reports, 2016, 6, 39537.	1.6	45
103	Photothermally Triggered Lipid Bilayer Phase Transition and Drug Release from Gold Nanorod and Indocyanine Green Encapsulated Liposomes. Langmuir, 2016, 32, 4554-4563.	1.6	31
104	Indocyanine Green-Loaded Liposomes for Light-Triggered Drug Release. Molecular Pharmaceutics, 2016, 13, 2095-2107.	2.3	102
105	Human corneal cell culture models for drug toxicity studies. Drug Delivery and Translational Research, 2016, 6, 660-675.	3.0	54
106	Light activated liposomes: Functionality and prospects in ocular drug delivery. Journal of Controlled Release, 2016, 244, 157-166.	4.8	78
107	Laminin-511 and laminin-521-based matrices for efficient hepatic specification of human pluripotent stem cells. Biomaterials, 2016, 103, 86-100.	5.7	60
108	HDAC inhibition in the <i>cpfl1 </i> mouse protects degenerating cone photoreceptors <i>in vivo </i> Human Molecular Genetics, 2016, 25, ddw275.	1.4	39

#	Article	IF	Citations
109	General Pharmacokinetic Model for Topically Administered Ocular Drug Dosage Forms. Pharmaceutical Research, 2016, 33, 2680-2690.	1.7	17
110	Interpretation of Ocular Melanin Drug Binding Assays. Alternatives to the Model of Multiple Classes of Independent Sites. Molecular Pharmaceutics, 2016, 13, 1251-1257.	2.3	14
111	Drug Distribution to Retinal Pigment Epithelium: Studies on Melanin Binding, Cellular Kinetics, and Single Photon Emission Computed Tomography/Computed Tomography Imaging. Molecular Pharmaceutics, 2016, 13, 2977-2986.	2.3	36
112	Hepatic differentiation of human pluripotent stem cells on human liver progenitor HepaRG-derived acellular matrix. Experimental Cell Research, 2016, 341, 207-217.	1.2	23
113	Intracellular PK/PD Relationships of Free and Liposomal Doxorubicin: Quantitative Analyses and PK/PD Modeling. Molecular Pharmaceutics, 2016, 13, 1358-1365.	2.3	27
114	Prediction of Ocular Drug Distribution from Systemic Blood Circulation. Molecular Pharmaceutics, 2016, 13, 2906-2911.	2.3	39
115	Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma. Oncolmmunology, 2016, 5, e1105429.	2.1	70
116	Detection of Phase Transition in Photosensitive Liposomes by Advanced QCM. Journal of Physical Chemistry C, 2015, 119, 21395-21403.	1.5	14
117	Modulatory Effect of Human Plasma on the Internal Nanostructure and Size Characteristics of Liquid-Crystalline Nanocarriers. Langmuir, 2015, 31, 5042-5049.	1.6	59
118	Undefined role of mucus as a barrier in ocular drug delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 96, 442-446.	2.0	78
119	Intravitreal clearance and volume of distribution of compounds in rabbits: In silico prediction and pharmacokinetic simulations for drug development. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 95, 215-226.	2.0	108
120	Light induced cytosolic drug delivery from liposomes with gold nanoparticles. Journal of Controlled Release, 2015, 203, 85-98.	4.8	113
121	Novel biodegradable polyesteramide microspheres for controlled drug delivery in Ophthalmology. Journal of Controlled Release, 2015, 211, 105-117.	4.8	85
122	Exploring the structure–activity relationships of ABCC2 modulators using a screening approach. Bioorganic and Medicinal Chemistry, 2015, 23, 3513-3525.	1.4	15
123	Oxidative Stress Protection by Exogenous Delivery of rhHsp70 Chaperone to the Retinal Pigment Epithelium (RPE), a Possible Therapeutic Strategy Against RPE Degeneration. Pharmaceutical Research, 2015, 32, 211-221.	1.7	43
124	Rabbit as an animal model for intravitreal pharmacokinetics: Clinical predictability and quality of the published data. Experimental Eye Research, 2015, 137, 111-124.	1.2	167
125	Encapsulated cells for long-term secretion of soluble VEGF receptor 1: Material optimization and simulation of ocular drug response. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 95, 387-397.	2.0	19
126	Breath figure templated semifluorinated block copolymers with tunable surface properties and binding capabilities. Journal of Applied Polymer Science, 2015, 132, .	1.3	8

#	Article	IF	CITATIONS
127	High-throughput in vitro drug release and pharmacokinetic simulation as a tool for drug delivery system development: Application to intravitreal ocular administration. International Journal of Pharmaceutics, 2014, 477, 469-475.	2.6	9
128	Technetium-99m-labeled nanofibrillar cellulose hydrogel for in vivo drug release. European Journal of Pharmaceutical Sciences, 2014, 65, 79-88.	1.9	60
129	A critical assessment of in vitro tissue models for ADME and drug delivery. Journal of Controlled Release, 2014, 190, 94-114.	4.8	32
130	SPECT/CT imaging of radiolabeled cubosomes and hexosomes forÂpotential theranostic applications. Biomaterials, 2013, 34, 8491-8503.	5.7	71
131	Nanostructured aqueous dispersions of citrem interacting with lipids and PEGylated lipids. RSC Advances, 2013, 3, 24576.	1.7	23
132	Characterization of reducible peptide oligomers as carriers for gene delivery. International Journal of Pharmaceutics, 2013, 441, 736-747.	2.6	28
133	Independent versus Cooperative Binding in Polyethylenimine–DNA and Poly(<scp>l</scp> -lysine)–DNA Polyplexes. Journal of Physical Chemistry B, 2013, 117, 10405-10413.	1.2	29
134	Prediction of the Vitreal Half-Life of Small Molecular Drug-Like Compounds. Pharmaceutical Research, 2012, 29, 3302-3311.	1.7	28
135	Generation of hESC-derived retinal pigment epithelium on biopolymer coated polyimide membranes. Biomaterials, 2012, 33, 8047-8054.	5.7	71
136	Characterization of Oil-Free and Oil-Loaded Liquid-Crystalline Particles Stabilized by Negatively Charged Stabilizer Citrem. Langmuir, 2012, 28, 11755-11766.	1.6	39
137	Pre-Targeting and Direct Immunotargeting of Liposomal Drug Carriers to Ovarian Carcinoma. PLoS ONE, 2012, 7, e41410.	1.1	50
138	Analysis of cause of failure of new targeting peptide in PEGylated liposome: Molecular modeling as rational design tool for nanomedicine. European Journal of Pharmaceutical Sciences, 2012, 46, 121-130.	1.9	58
139	Impact of probe compound in MRP2 vesicular transport assays. European Journal of Pharmaceutical Sciences, 2012, 46, 100-105.	1.9	30
140	Organotypic cell cultures and two-photon imaging: Tools for in vitro and in vivo assessment of percutaneous drug delivery and skin toxicity. Journal of Controlled Release, 2012, 161, 656-667.	4.8	28
141	Role of Polyplex Intermediate Species on Gene Transfer Efficiency: Polyethylenimineâ^DNA Complexes and Time-Resolved Fluorescence Spectroscopy. Journal of Physical Chemistry B, 2011, 115, 1895-1902.	1.2	33
142	Study of PEGylated Lipid Layers as a Model for PEGylated Liposome Surfaces: Molecular Dynamics Simulation and Langmuir Monolayer Studies. Langmuir, 2011, 27, 7788-7798.	1.6	95
143	Mechanisms of polyethylenimineâ€mediated DNA delivery: free carrier helps to overcome the barrier of cellâ€surface glycosaminoglycans. Journal of Gene Medicine, 2011, 13, 402-409.	1.4	43
144	Prediction of the Corneal Permeability of Drug-Like Compounds. Pharmaceutical Research, 2010, 27, 1398-1407.	1.7	46

#	Article	IF	Citations
145	Gold-embedded photosensitive liposomes for drug delivery: Triggering mechanism and intracellular release. Journal of Controlled Release, 2010, 147, 136-143.	4.8	140
146	Barrier analysis of periocular drug delivery to the posterior segment. Journal of Controlled Release, 2010, 148, 42-48.	4.8	130
147	Filter-cultured ARPE-19 cells as outer blood–retinal barrier model. European Journal of Pharmaceutical Sciences, 2010, 40, 289-296.	1.9	59
148	Effluxing ABC transporters in human corneal epithelium. Journal of Pharmaceutical Sciences, 2010, 99, 1087-1098.	1.6	53
149	Paracellular Porosity and Pore Size of the Human Intestinal Epithelium in Tissue and Cell Culture Models. Journal of Pharmaceutical Sciences, 2010, 99, 2166-2175.	1.6	127
150	Structural Elucidation of Light Activated Vesicles. Journal of Physical Chemistry Letters, 2010, 1, 962-966.	2.1	40
151	p62/sequestosome 1 as a regulator of proteasome inhibitor-induced autophagy in human retinal pigment epithelial cells. Molecular Vision, 2010, 16, 1399-414.	1.1	62
152	Gene expression analysis in SV-40 immortalized human corneal epithelial cells cultured with an air-liquid interface. Molecular Vision, 2010, 16, 2109-20.	1.1	24
153	Intracellular DNA release and elimination correlate poorly with transgene expression after non-viral transfection. Journal of Controlled Release, 2009, 136, 226-231.	4.8	31
154	Efflux Protein Expression in Human Retinal Pigment Epithelium Cell Lines. Pharmaceutical Research, 2009, 26, 1785-1791.	1.7	72
155	Low molecular weight hyaluronan shielding of DNA/PEI polyplexes facilitates CD44 receptor mediated uptake in human corneal epithelial cells. Journal of Gene Medicine, 2008, 10, 70-80.	1.4	69
156	Interaction of lipid nanoparticles with human epidermis and an organotypic cell culture model. International Journal of Pharmaceutics, 2008, 354, 180-195.	2.6	79
157	Passive oral drug absorption can be predicted more reliably by experimental than computational modelsâ€"Fact or myth. European Journal of Pharmaceutical Sciences, 2008, 34, 129-139.	1.9	25
158	Current and future ophthalmic drug delivery systems A shift to the posterior segment. Drug Discovery Today, 2008, 13, 135-143.	3.2	356
159	Glycosaminoglycan-resistant and pH-sensitive lipid-coated DNA complexes produced by detergent removal method. Journal of Controlled Release, 2008, 131, 145-149.	4.8	17
160	Comparison of rat epidermal keratinocyte organotypic culture (ROC) with intact human skin: Lipid composition and thermal phase behavior of the stratum corneum. Biochimica Et Biophysica Acta - Biomembranes, 2008, 1778, 824-834.	1.4	35
161	Time-Resolved Fluorescence Spectroscopy Reveals Functional Differences of Cationic Polymerâ^'DNA Complexes. Journal of the American Chemical Society, 2008, 130, 11695-11700.	6.6	45
162	Synthesis and Cellular Uptake of Fluorescently Labeled Multivalent Hyaluronan Disaccharide Conjugates of Oligonucleotide Phosphorothioates. Bioconjugate Chemistry, 2008, 19, 2549-2558.	1.8	17

#	Article	IF	CITATIONS
163	Temperature-Sensitive Poly(<i>N</i> -(2-hydroxypropyl)methacrylamide mono/dilactate)-Coated Liposomes for Triggered Contents Release. Bioconjugate Chemistry, 2007, 18, 2131-2136.	1.8	66
164	Corneal epithelium as a platform for secretion of transgene products after transfection with liposomal gene eyedrops. Journal of Gene Medicine, 2007, 9, 208-216.	1.4	33
165	Polyplex-mediated gene transfer and cell cycle: effect of carrier on cellular uptake and intracellular kinetics, and significance of glycosaminoglycans. Journal of Gene Medicine, 2007, 9, 479-487.	1.4	65
166	Rat epidermal keratinocyte organotypic culture (ROC) compared to human cadaver skin: The effect of skin permeation enhancers. European Journal of Pharmaceutical Sciences, 2007, 30, 240-250.	1.9	16
167	Gold nanoparticles enable selective light-induced contents release from liposomes. Journal of Controlled Release, 2007, 122, 86-93.	4.8	223
168	Binding of Betaxolol, Metoprolol and Oligonucleotides to Synthetic and Bovine Ocular Melanin, and Prediction of Drug Binding to Melanin in Human Choroid-Retinal Pigment Epithelium. Pharmaceutical Research, 2007, 24, 2063-2070.	1.7	50
169	Epidermal cell culture model with tight stratum corneum as a tool for dermal gene delivery studies. International Journal of Pharmaceutics, 2006, 307, 188-193.	2.6	6
170	Computational Prediction of Oral Drug Absorption Based on Absorption Rate Constants in Humans. Journal of Medicinal Chemistry, 2006, 49, 3674-3681.	2.9	69
171	Drug transport in corneal epithelium and blood–retina barrier: Emerging role of transporters in ocular pharmacokinetics. Advanced Drug Delivery Reviews, 2006, 58, 1136-1163.	6.6	294
172	Transscleral drug delivery to the posterior eye: Prospects of pharmacokinetic modeling. Advanced Drug Delivery Reviews, 2006, 58, 1164-1181.	6.6	138
173	Challenges and obstacles of ocular pharmacokinetics and drug delivery. Advanced Drug Delivery Reviews, 2006, 58, 1131-1135.	6.6	782
174	Rat epidermal keratinocyte organotypic culture (ROC) as a model for chemically induced skin irritation testing. Toxicology and Applied Pharmacology, 2005, 208, 233-241.	1.3	12
175	The role of cell cycle on polyplex-mediated gene transfer into a retinal pigment epithelial cell line. Journal of Gene Medicine, 2005, 7, 466-476.	1.4	35
176	Permeability of Retinal Pigment Epithelium: Effects of Permeant Molecular Weight and Lipophilicity., 2005, 46, 641.		232
177	Long-Lasting Secretion of Transgene Product from Differentiated and Filter-Grown Retinal Pigment Epithelial Cells After Nonviral Gene Transfer. Current Eye Research, 2005, 30, 345-353.	0.7	26
178	Cell culture models of the ocular barriers. European Journal of Pharmaceutics and Biopharmaceutics, 2005, 60, 207-225.	2.0	245
179	Starch acetate microparticles for drug delivery into retinal pigment epitheliumâ€"in vitro study. Journal of Controlled Release, 2004, 98, 407-413.	4.8	52
180	Drug permeation in biomembranes. European Journal of Pharmaceutical Sciences, 2004, 23, 13-47.	1.9	167

#	Article	lF	Citations
181	Substrates and inhibitors of efflux proteins interfere with the MTT assay in cells and may lead to underestimation of drug toxicity. European Journal of Pharmaceutical Sciences, 2004, 23, 181-188.	1.9	97
182	Cell-surface glycosaminoglycans inhibit cation-mediated gene transfer. Journal of Gene Medicine, 2004, 6, 405-414.	1.4	94
183	Neural retina limits the nonviral gene transfer to retinal pigment epithelium in an in vitro bovine eye model. AAPS Journal, 2004, 6, 72-80.	2.2	49
184	Vitreous is a barrier in nonviral gene transfer by cationic lipids and polymers. Pharmaceutical Research, 2003, 20, 576-583.	1.7	124
185	Ocular pharmacokinetic modeling using corneal absorption and desorption rates from in vitro permeation experiments with cultured corneal epithelial cells. Pharmaceutical Research, 2003, 20, 1409-1416.	1.7	32
186	Paracellular and passive transcellular permeability in immortalized human corneal epithelial cell culture model. European Journal of Pharmaceutical Sciences, 2003, 20, 99-106.	1.9	76
187	Epidermal cell culture model derived from rat keratinocytes with permeability characteristics comparable to human cadaver skin. European Journal of Pharmaceutical Sciences, 2003, 20, 107-113.	1.9	36
188	Extracellular and intracellular barriers in non-viral gene delivery. Journal of Controlled Release, 2003, 93, 213-217.	4.8	147
189	Retina-specific gene expression and improved DNA transfection in WERI-Rb1 retinoblastoma cells. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2003, 1628, 169-176.	2.4	7
190	Simultaneous determination of eight \hat{l}^2 -blockers by gradient high-performance liquid chromatography with combined ultraviolet and fluorescence detection in corneal permeability studies in vitro. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 772, 81-87.	1.2	63
191	VitaminÂC enhances differentiation of a continuous keratinocyte cell line (REK) into epidermis with normal stratum corneum ultrastructure and functional permeability barrier. Histochemistry and Cell Biology, 2001, 116, 287-297.	0.8	66
192	Formation of Permeability Barrier in Epidermal Organotypic Culture for Studies on Drug Transport. Journal of Investigative Dermatology, 2001, 117, 1322-1324.	0.3	24
193	A novel drug-regulated gene expression system based on the nuclear receptor constitutive androstane receptor (CAR). Pharmaceutical Research, 2001, 18, 146-150.	1.7	45
194	Extracellular Glycosaminoglycans Modify Cellular Trafficking of Lipoplexes and Polyplexes. Journal of Biological Chemistry, 2001, 276, 33875-33880.	1.6	182
195	Water-activated, pH-controlled patch in transdermal administration of timolol. European Journal of Pharmaceutical Sciences, 2000, 11 , 19 -24.	1.9	16
196	Gene Delivery and Expression in Human Retinal Pigment Epithelial Cells: Effects of Synthetic Carriers, Serum, Extracellular Matrix and Viral Promoters. Journal of Drug Targeting, 2000, 7, 413-421.	2.1	44
197	Novel cationic amphiphilic 1,4-dihydropyridine derivatives for DNA delivery. Biochimica Et Biophysica Acta - Biomembranes, 2000, 1509, 451-466.	1.4	78
198	Liposome–skin interactions and their effects on the skin permeation of drugs. European Journal of Pharmaceutical Sciences, 1999, 7, 279-286.	1.9	146

#	Article	IF	Citations
199	Interactions of polymeric and liposomal gene delivery systems with extracellular glycosaminoglycans: physicochemical and transfection studies. Biochimica Et Biophysica Acta - Biomembranes, 1999, 1415, 331-341.	1.4	311
200	Evaluation of cytotoxicity of various ophthalmic drugs, eye drop excipients and cyclodextrins in an immortalized human corneal epithelial cell line. Pharmaceutical Research, 1998, 15, 1275-1280.	1.7	122
201	Different effects of pH on the permeation of pilocarpine and pilocarpine prodrugs across the isolated rabbit cornea. European Journal of Pharmaceutical Sciences, 1998, 6, 169-176.	1.9	19
202	Estimation of pore size and pore density of biomembranes from permeability measurements of polyethylene glycols using an effusion-like approach. Journal of Controlled Release, 1997, 49, 97-104.	4.8	51
203	Interaction of liposomes with human skin in vitro — The influence of lipid composition and structure. Lipids and Lipid Metabolism, 1996, 1304, 179-189.	2.6	210
204	Amphiphilic properties of pilocarpine prodrugs. International Journal of Pharmaceutics, 1996, 133, 171-178.	2.6	17
205	Ocular absorption following topical delivery. Advanced Drug Delivery Reviews, 1995, 16, 3-19.	6.6	299
206	Controlled ocular timolol delivery: systemic absorption and intraocular pressure effects in humans. Pharmaceutical Research, 1994, 11, 1278-1282.	1.7	48
207	Oligonucleotide-cationic liposome interactions. A physicochemical study. Biochimica Et Biophysica Acta - Biomembranes, 1994, 1195, 115-123.	1.4	93
208	Transdermal iontophoresis of sotalol and salicylate; the effect of skin charge and penetration enhancers. Journal of Controlled Release, 1993, 26, 109-117.	4.8	28
209	Minimizing systemic absorption of topically administered ophthalmic drugs. Survey of Ophthalmology, 1993, 37, 435-456.	1.7	236
210	Permeability of pilocarpic acid diesters across albino rabbit cornea in vitro. International Journal of Pharmaceutics, 1991, 74, 221-228.	2.6	31
211	Controlled drug delivery devices for experimental ocular studies with timolol 1. In vitro release studies. International Journal of Pharmaceutics, 1990, 61, 235-240.	2.6	24
212	Application Site Dependent Ocular Absorption of Timolol. Journal of Ocular Pharmacology and Therapeutics, 1988, 4, 335-343.	0.6	16
213	Concentrationâ€dependent precorneal loss of pilocarpine in rabbit eyes. Acta Ophthalmologica, 1985, 63, 502-506.	0.6	9
214	Effect of ocular pigmentation on pilocarpine pharmacology in the rabbit eye. I. Drag distribution and metabolism. International Journal of Pharmaceutics, 1984, 18, 17-24.	2.6	32
215	Disposition of ophthalmic timolol in treated and untreated rabbit eyes. A multiple and single dose study. Experimental Eye Research, 1984, 38, 203-206.	1.2	44
216	OCULAR DISTRIBUTION OF TOPICALLY APPLIED ADRENALINE IN ALBINO AND PIGMENTED RABBITS. Acta Ophthalmologica, 1984, 62, 753-762.	0.6	10